{"id":2560,"date":"2018-05-01T12:03:00","date_gmt":"2018-05-01T10:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/fluorchinolone-und-aortenaneurysmen"},"modified":"2018-05-01T12:03:00","modified_gmt":"2018-05-01T10:03:00","slug":"fluorchinolone-und-aortenaneurysmen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/fluorchinolone-und-aortenaneurysmen","title":{"rendered":"Fluorchinolone und Aortenaneurysmen"},"content":{"rendered":"<p>Chinolone bzw. Fluorchinolone (FC) geh\u00f6ren zu den sehr h\u00e4ufig eingesetzten Antibiotikagruppen. In Deutschland wurden 2016 im ambulanten Bereich ca. 32 Mio. und in \u00d6sterreich 2015 4,1 Mio. Tagesdosen (DDD = Daily Defined Doses) verordnet (1, 2). Sehnenentz\u00fcndungen und Sehnenrupturen, besonders der Achillessehne, sind seltene, aber bedeutsame Nebenwirkungen einer Behandlung mit FC (laut Fachinformationen \u201eselten\u201c, also [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chinolone bzw. Fluorchinolone (FC) geh\u00f6ren zu den sehr h\u00e4ufig eingesetzten Antibiotikagruppen. In Deutschland wurden 2016 im ambulanten Bereich ca. 32 Mio. und in \u00d6sterreich 2015 4,1 Mio. Tagesdosen (DDD = Daily Defined Doses) verordnet (1, 2). Sehnenentz\u00fcndungen und Sehnenrupturen, besonders der Achillessehne, sind seltene, aber bedeutsame Nebenwirkungen einer Behandlung mit FC (laut Fachinformationen \u201eselten\u201c, also [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5037,343,4309,294,1685,1684,295,1049],"class_list":["post-2560","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-aneurysma","tag-antibiotika","tag-aortenaneurysma","tag-ciprofloxacin","tag-fluorchinolone","tag-fluorochinolone","tag-gyrasehemmer","tag-norfloxacin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2560"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2560\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}